Source-grounded facts extracted from Eledon Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Eledon Pharmaceuticals, Inc.: Extended exculpation protection to officers to the fullest extent permitted by Delaware law.
“a Certificate of Amendment (the “Officer Exculpation Amendment”) to amend the Certificate of Incorporation to extend exculpation protection to officers, to the fullest extent permitted by Delaware law”
Eledon Pharmaceuticals, Inc.: Increased authorized shares of common stock from 200,000,000 to 300,000,000.
“the Company filed the following with the Secretary of State of the State of Delaware: • a Certificate of Amendment (the “Authorized Share Increase Amendment”) to the Company’s Restated Certificate of Incorporation (as amended, the “Certificate of Incorporation”) to amend the Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 to 300,000,000 shares”
Eledon Pharmaceuticals, Inc. reported the quarter ended March 31, 2024 results: net income net loss of $10.3 million, EPS $0.34 per share.
“The Company reported a net loss of $10.3 million, or $0.34 per share, for the three months ended March 31, 2024, compared to a net loss of $10.8 million, or $0.75 per share, for the same period in 2023.”
Eledon Pharmaceuticals, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2024-05-06).
“In connection with the Private Placement, the Company entered into a registration rights agreement, dated May 6, 2024 (the “Registration Rights Agreement”), with the Purchasers, pursuant to which, among other things, the Company will (i) prepare and file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-3 to register for resale the Shares and the shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants within 20 calendar days, and (ii) use its reasonable best efforts to have the registration statement declared effective promptly after filing, and in any event no later than 60 days after the date of the Securities Purchase Agreement (or 90 days after the date of the Securities Purchase Agreement if the registration statement is reviewed by the SEC).”
Eledon Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional and accredited investors (the "Purchasers") valued at approximately $50 million (effective 2024-05-06).
“On May 6, 2024, Eledon Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”) an aggregate of 13,110,484 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) at a price of $2.37 per share, and pre-funded warrants (the “Pre-Funded Warrants”) at a price of $2.369 per underlying share, which are exercisable to purchase 7,989,516 shares of Common Stock at an exercise price of $0.001 per share.”
Eledon Pharmaceuticals, Inc. reported the year ended December 31, 2023 results: net income net loss of $40.3 million, or $1.64 per share, EPS $1.64 per share.
“The Company reported a net loss of $40.3 million, or $1.64 per share, for the year ended December 31, 2023, compared to a net loss of $88.0 million, or $6.16 per share, in 2022.”
Eledon Pharmaceuticals, Inc. reported the three months ended December 31, 2023 results: net income net loss of $9.6 million, or $0.32 per share, EPS $0.32 per share.
“The Company reported a net loss of $9.6 million, or $0.32 per share, for the three months ended December 31, 2023, compared to a net loss of $58.4 million, or $4.09 per share, for the same period in 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.